ArticleThe Prostate2020
The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume.
Article in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Prevention of Postoperative Urethral Strictures by Irrigation with 5-Fluorouracil via a Modified Urinary Catheter.Medicina (Kaunas, Lithuania) · 2024Trial
- Association between metabolic syndrome and BPH/LUTS among community-dwelling men in Northern China: a population-based study.BMC urology · 2025Article
- Association between insulin resistance and prostate volume: A 4-year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.BJUI compass · 2025Article
- Article
- Risk factors for benign prostatic hyperplasia: a comprehensive review.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Phenotyping Men With Lower Urinary Tract Symptoms: Results From the Symptoms of Lower Urinary Tract Dysfunction Research Network.Neurourology and urodynamics · 2025Observational
- Relative fat mass is a valuable predictor of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: clinical implications.Translational andrology and urology · 2024Article
- Association between dietary niacin intake and benign prostatic hyperplasia: a population-based results from NHANES 2003-2008.Journal of health, population, and nutrition · 2024Article
- Intrinsic and extrinsic factors causing hyperplasia of the prostate.International journal of urology : official journal of the Japanese Urological Association · 2024Review
- A Mendelian randomization study between metabolic syndrome and its components with prostate cancer.Scientific reports · 2024Article
- Correlation between metabolic syndrome and periurethral prostatic fibrosis: results of a prospective study.BMC urology · 2024Article
- Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases.Prostate cancer and prostatic diseases · 2023Article
- Adiponectin can be a good predictor of urodynamic detrusor underactivity: a prospective study in men with lower urinary tract symptoms.World journal of urology · 2023Article
- Overview of BPH: Symptom Relief with Dietary Polyphenols, Vitamins and Phytochemicals by Nutraceutical Supplements with Implications to the Prostate Microbiome.International journal of molecular sciences · 2023Review
- Aging and aging-related diseases: from molecular mechanisms to interventions and treatments.Signal transduction and targeted therapy · 2022Review
- Relationship between outpatient duration of young outpatient physicians and lower urinary tract symptoms and sexual dysfunction.Translational andrology and urology · 2022Article
- Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.World journal of urology · 2021Article
- Endocrinology of the Aging Prostate: Current Concepts.Frontiers in endocrinology · 2021Review
- Comparison of the predictive value of anthropometric indicators for the risk of benign prostatic hyperplasia in southern China.Asian journal of andrologyArticle
- Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells.Asian journal of andrologyArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men. SUBJECTS AND
methodsWe analyzed clinical data obtained from 506 ostensibly healthy men who underwent routine health check-ups and recruited 415 subjects from a group of previously studied men after 4 years. We evaluated the associations of major pathological factors of MetS, including insulin resistance, subclinical inflammatory state, and sex hormone changes, with PV, the risk of BPH and the clinical progression of BPH/LUTS by using multiple linear regression and logistic regression.
resultsAfter adjustment for age, insulin, HOMA (homeostatic model assessment) index, leptin, resistin, adiponectin, C-reactive protein, tumor necrosis factor-α (TNF-α), sex hormone-binding globulin, and testosterone levels were significantly associated with PV (all P < .05), and in the age-adjusted logistic regression model, positive associations of resistin and TNF-α with BPH/LUTS were found (OR, 1.662, P = .007 and OR, 1.044, P < .001, respectively). Predictors of BPH/LUTS clinical progression were significantly correlated with MetS and TNF-α. The group with higher TNF-α levels had a higher rate of newly diagnosed BPH (9.5% vs 19.1%, P = .006) and a greater increase in PV levels (0.61 ± 0.08 vs 1.09 ± 0.35 cm
conclusionsMetS and its pathological factors were associated with an increased PV and an increased risk of BPH/LUTS that is more prone to clinical progression. TNF-α may serve as an early biological indicator to identify which patients with BPH/LUTS are at higher risk of unfavorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.